News

Check out highlights from news published on Day 2 of the EADV Congress 2026, spanning vitiligo, HS, atopic dermatitis, and more.

Joseph Rossano, MD, MS, discusses the SCOUT-HCM trial, mavacamten’s expanded indication, and what it means for pediatric oHCM.

FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.

Facial and total body repigmentation with upadacitinib kept rising through Week 76 in Viti-Up, with higher responses when NB-UVB was added.

An ARCADIA investigator says patients in practice match the 3-year trial results and outlines next steps for IL-31 research.

DBV has requested priority review for the epicutaneous patch, supported by phase 3 VITESSE data showing a 31.8-point responder rate gain vs placebo.

Up to 91% of patients reached EASI-75 at week 152 in the ARCADIA LTE, with consistent safety and gains in itch and quality of life.

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.

Earlier bimekizumab treatment was tied to higher IHS4-100 rates at 3 years in hidradenitis suppurativa, per post hoc BE HEARD data at EADV 2026.

At EADV 2026, Julia Mhlaba Riley, MD, discussed how hidradenitis suppurativa presents in skin of color and ways to close diagnostic and treatment gaps.

EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.

FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.

Heavy drinking rose >36% since 2018 among middle-aged adults. A hepatologist on screening, sex-specific thresholds, and pandemic effects.

Jesus Almendral, MD, and Kanika Mody, MD, join the HCPLive team to discuss increases in hypertensive heart disease, heart failure, and other conditions.

Check out highlights from news published on Day 1 of the EADV Congress 2026, spanning CSU, atopic dermatitis, HS, and more.

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Tulisokibart met its HiSCR50 primary endpoint at 16 weeks in the phase 2b MK-7240-012 trial assessing moderate to severe hidradenitis suppurativa.

Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.

Intralesional BO-112 met its main endpoint in the phase 2b SPOTLIGHT-204 trial, with 61% of patients with resectable basal cell carcinoma responding.

Zasocitinib achieved PASI 100 in 36.5% of patients vs 13.9% with deucravacitinib at week 16 in the phase 3 LATITUDE Atlas psoriasis trial.

The international SkinObservatory study found climate-related skin disease disproportionately affecting low-income nations at EADV 2026.

All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.

Dupilumab improved overall CU-Q2oL scores and 22 of 23 items vs placebo at 24 weeks in omalizumab-naive CSU, per a pooled CUPID A and C analysis.

Newly published results from the TRIUMPH-1 study have indicated the direct correlation between the triple agonist and several improvements to weight.

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Final ORIGIN 3 analysis shows a 76% lower risk of kidney disease progression vs placebo through 2 years.

Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.